Publications
255
Citations
1,674
Est. group size
~15
Recurring co-author estimate
Active years
22
Publishing since 2004
Typically publishes in teams of ~18 · 19% small-team papers (≤3 authors) · across 17 venues
- Ziftomenib in Relapsed or Refractory <i>NPM1</i> -Mutated AML
Journal of Clinical Oncology · 2025
- Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms
Blood Neoplasia · 2025
- Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy
Blood Advances · 2025
- Ziftomenib in relapsed/refractory (R/R) <i>NPM1</i> -mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study.
Journal of Clinical Oncology · 2025
- Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV).
Journal of Clinical Oncology · 2025
- Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study
Blood · 2025
- Shorespan-007: Phase 3 study of bomedemstat versus hydroxyurea in essential thrombocythemia naive to cytoreductive therapy.
Journal of Clinical Oncology · 2025
- POSTER: MPN-785 Results From VERIFY, an International, Randomized, Phase 3, Double-Blind, Placebo-Controlled Study of Rusfertide (First-in-Class Hepcidin Mimetic) for Treatment of Polycythemia Vera (PV)
Clinical Lymphoma Myeloma & Leukemia · 2025
- ORAL ABSTRACT: AML-789 Ziftomenib in Relapsed/Refractory NPM1-Mutant Acute Myeloid Leukemia (AML): Phase 1b/2 Results From the Pivotal KOMET-001 Study
Clinical Lymphoma Myeloma & Leukemia · 2025
- POSTER: AML-789 Ziftomenib in Relapsed/Refractory NPM1-Mutant Acute Myeloid Leukemia (AML): Phase 1b/2 Results From the Pivotal KOMET-001 Study
Clinical Lymphoma Myeloma & Leukemia · 2025
- MPN-785: Results From VERIFY, an International, Randomized, Phase 3, Double-Blind, Placebo-Controlled Study of Rusfertide (First-in-Class Hepcidin Mimetic) for Treatment of Polycythemia Vera (PV)
Clinical Lymphoma Myeloma & Leukemia · 2025
- AML-789: Ziftomenib in Relapsed/Refractory NPM1-Mutant Acute Myeloid Leukemia (AML): Phase 1b/2 Results From the Pivotal KOMET-001 Study
Clinical Lymphoma Myeloma & Leukemia · 2025
- Shorespan-017: Phase 3 extension study for safety of bomedemstat in participants with essential thrombocythemia who received bomedemstat from a prior clinical study
Blood · 2025
- Comprehensive analyses of patient-reported outcomes from the phase 3 VERIFY study of rusfertide or placebo plus current standard of care for polycythemia vera
Blood · 2025
- Should dermatologic examinations become routine standard of care in patients with polycythemia vera? Observations from the phase 3 VERIFY study prior to rusfertide exposure
Blood · 2025
- Blood×40
- Clinical Lymphoma Myeloma & Leukemia×18
- Journal of Clinical Oncology×8
- Leukemia & lymphoma/Leukemia and lymphoma×7
- Blood Advances×4
- Veena Fauble
Medicine · University of Michigan
- Malathi Kandarpa
Medicine · University of Michigan
- James Yoon
Medicine · University of Michigan
- Andrea Sipos
Medicine · University of Michigan
- Harrison S. Greenbaum
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile